Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
5/31/2026, 12:00:00 AM
Announced positive Phase 3 results for cancer drug Retevmo in early-stage RET fusion-positive non-small cell lung cancer, showing an 83% reduction in the risk of disease recurrence or death; high impact due to breakthrough clinical data expected
Korean Translation
초기 RET 융합 양성 비소세포폐암 항암제 레테브모(Retevmo)의 3상 임상에서 질병 재발 위험을 83% 감소시킨 결과가 발표됨. 획기적 데이터에 따른 높은 시장 영향이 예상됨
Related Recent Events
Tempus AI Inc (TEM) · Earnings Release
Tempus AI is scheduled to report its Q2 2026 financial results; earnings releases typically result in price moves of 5% or more, scheduled.
8/14/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
Next earnings release for Q2 2026 on 2026-08-03 is scheduled. Low importance is estimated for the scheduling announcement itself.
8/3/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet's Q2 2026 earnings release is scheduled.
7/28/2026, 12:00:00 AM
Intuitive Surgical Inc (ISRG) · Earnings Release
Intuitive Surgical's Q2 2026 earnings release, a major stock catalyst, is scheduled.
7/21/2026, 12:00:00 AM
Recursion Pharmaceauticals Inc (RXRX) · Other
2026 Annual Meeting of Stockholders scheduled for June 17, 2026. Market reaction not yet occurred; low importance assigned due to likely <5% price impact from annual meeting scheduled.
6/17/2026, 12:00:00 AM